Lawrence M. Alleva - 03 Aug 2026 Form 4 Insider Report for Galera Therapeutics, Inc. (GRTX)

Reporting relationship: Director
Issuer ticker: GRTX
Reported as of: 03 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Aug 2026, 16:22:26 UTC
Prior SEC filing: 05 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ J. Mel Sorensen, Attorney-in-Fact for Lawrence M. Alleva

Key filing fact

Lawrence M. Alleva filed Form 4 for Galera Therapeutics, Inc. (GRTX) on 05 Aug 2026.

Key facts

This page summarizes Lawrence M. Alleva's Form 4 filing for Galera Therapeutics, Inc. (GRTX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Aug 2026, 16:22.

Change

Previous filing in this sequence was filed on 05 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001553053 Primary reporting owner

Alleva Lawrence M

Relationship: Director
Address: C/O GALERA THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 225, MALVERN
Signature: /s/ J. Mel Sorensen, Attorney-in-Fact for Lawrence M. Alleva
Signature date: 05 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GRTX transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -11
Change %: -100%
Price
Shares after: 0
Date: 03 Aug 2026
Ownership: Direct
Footnotes: F1, F2, F3

GRTX transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -40
Change %: -100%
Price
Shares after: 0
Date: 03 Aug 2026
Ownership: By the Lawrence M. Alleva Revocable Trust.
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GRTX transaction Derivative

Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -240
Change %: -100%
Price
Shares after: 0
Date: 03 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 240
Exercise price: $8.20
Footnotes: F1, F2, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Lawrence M. Alleva is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

These numbers have been adjusted to reflect the 1-for-200 reverse stock split Galera Therapeutics, Inc. ("Galera") effected on July 12, 2026.

Footnote F2

Pursuant to an Agreement and Plan of Merger, dated as of April 14, 2026 (the "Merger Agreement"), by and among Galera, Obsidian Therapeutics, Inc. ("Obsidian"), Gazelle Parent, Inc. ("Parent"), Onyx MergerSub, Inc., a wholly owned subsidiary of Parent ("Obsidian Merger Sub"), and Gazelle Merger Subsidiary, Inc., a wholly owned subsidiary of Parent ("Galera Merger Sub"), on August 3, 2026, Galera merged with and into Galera Merger Sub, with Galera surviving as a wholly owned subsidiary of Parent (the "Galera Merger"), and Obsidian merged with and into Obsidian Merger Sub, with Obsidian surviving as a wholly owned subsidiary of Parent (together with the Galera Merger, the "Mergers").

Footnote F3

At the effective time of the Galera Merger (the "Galera Effective Time"), each outstanding share of Galera common stock (excluding any shares of Galera common stock held by stockholders who had exercised and perfected appraisal rights for such shares) was converted into the right to receive 0.7019 shares of Parent common stock (the "Galera Exchange Ratio").

Footnote F4

At the Galera Effective Time, each outstanding Galera stock option with an exercise price per share less than $15.62 (each, an "In-the-Money Option"), which was the closing trading price of a share of Galera common stock on the last full trading day on which the Galera common stock was traded prior to the date of the Galera Effective Time, became fully vested and was converted into shares of Parent common stock determined by (i) multiplying the number of shares of Galera common stock underlying the In-the-Money Option by the Galera Exchange Ratio (rounded down to the nearest whole share) then (ii) subtracting the number of shares of Parent common stock with a value equal to the exercise price and withholding taxes each required to be paid with respect to the net exercise of the In-the-Money Option, calculated pursuant to the formula set forth in Section 2.6(i) of the Merger Agreement.

SEC remarks

At the Galera Effective Time, each outstanding Galera stock option that was not an In-the-Money Option (each, a "Non-In-the-Money Option") was cancelled for no consideration, which cancellation is exempt from Section 16 of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16a-4(d) and Rule 16b-6(d) thereunder. Accordingly, the Reporting Person's Non-In-the-Money Options that were cancelled in connection with the Mergers are not reported herein.